A detailed history of Man Group PLC transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Man Group PLC holds 110,626 shares of NUVB stock, worth $258,864. This represents 0.0% of its overall portfolio holdings.

Number of Shares
110,626
Previous 260,279 57.5%
Holding current value
$258,864
Previous $947,000 65.89%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$2.58 - $3.69 $386,104 - $552,219
-149,653 Reduced 57.5%
110,626 $323,000
Q1 2024

May 15, 2024

BUY
$1.46 - $3.97 $32,045 - $87,137
21,949 Added 9.21%
260,279 $947,000
Q4 2023

Feb 14, 2024

BUY
$0.96 - $1.53 $228,796 - $364,644
238,330 New
238,330 $359,000
Q3 2022

Nov 14, 2022

BUY
$0.29 - $4.04 $348 - $4,848
1,200 Added 2.23%
55,100 $123,000
Q2 2022

Aug 15, 2022

BUY
$3.24 - $5.85 $127,656 - $230,490
39,400 Added 271.72%
53,900 $175,000
Q1 2022

May 16, 2022

BUY
$4.6 - $8.83 $66,700 - $128,035
14,500 New
14,500 $76,000

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $508M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.